Buscar
Mostrando ítems 1-10 de 31
Editorial: Toward a Melanoma Dendritic Cell Vaccine using Neoantigens
(International Journal of Clinical Dermatology & Research (IJCDR), 2017)
Identification of breast cancer neoantigens using in silico methodologies
(Fiocruz/Instituto de Tecnologia em Imunobiológicos, 2019)
neoANT:HILL: uma ferramenta integrada para a detecção de potenciais neoantígenos
(BrasilUFRNPROGRAMA DE PÓS-GRADUAÇÃO EM BIOINFORMÁTICA, 2019-04-18)
In recent years, neoantigens have generated great interest in immunotherapy due to
its ability to elicit antitumor immune responses. Neoantigens arise from specific
somatic mutations and it can be present by HLA molecules ...
Traces of immunoediting during myeloproliferative neoplasm to secondary acute myeloid leukemia transition
(Fiocruz/Instituto de Tecnologia em Imunobiológicos, 2018)
Immune landscape in esophageal squamous cell carcinoma
(Fiocruz/Instituto de Tecnologia em Imunobiológicos, 2018)
Identificación y caracterización de linfocitos T neoantígeno específicos de donantes sanos con fines de inmunoterapia en cáncer
(Universidad Nacional de ColombiaBogotá - Medicina - Maestría en InmunologíaFacultad de MedicinaBogotá, ColombiaUniversidad Nacional de Colombia - Sede Bogotá, 2022-11-15)
La inmunoterapia basada en neoantígenos permite estimular el sistema inmune del paciente con cáncer al inducir una respuesta antitumoral dirigida mediada por Linfocitos T (LT). Los neoantígenos son generados por ...
Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF
(Frontiers Media S.A., 2020-06)
The CSF-470 vaccine consists of lethally-irradiated allogeneic cells derived from four cutaneous melanoma cell lines administered plus BCG and GM-CSF as adjuvants. In an adjuvant phase II study vs. IFN-α2b, the vaccine ...
An analysis of natural T cell responses to predicted tumor neoepitopes
(Frontiers Research Foundation, 2017-11)
Personalization of cancer immunotherapies such as therapeutic vaccines and adoptive T-cell therapy may benefit from efficient identification and targeting of patient-specific neoepitopes. However, current neoepitope ...
MuPeXI: prediction of neo-epitopes from tumor sequencing data
(Springer, 2017-09)
Personalization of immunotherapies such as cancer vaccines and adoptive T cell therapy depends on identification of patient-specific neo-epitopes that can be specifically targeted. MuPeXI, the mutant peptide extractor and ...